News/ News/ Oncology Roche claims EU okay for Herceptin/Perjeta combination Phesgo Phil Taylor EU, HER2-positive breast cancer, Oncology, Phesgo, regulatory approval, Roche 0 Comment Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta Share X Roche claims EU okay for Herceptin/Perjeta combination Phesgo https://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/
News/ News/ Oncology Roche’s Herceptin/Perjeta combo product nears EU approval Phil Taylor CHMP, herceptin, Perjeta, Phesgo, Roche, Xofluza 0 Comment The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin Share X Roche’s Herceptin/Perjeta combo product nears EU approval https://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/